1. $GALT my chart shows a close around 5.80 today

  2. $GALT buy and PT of 16... That s almost triple of now.. Gonna pick up more

  3. $GALT MLV and Co. analyst reiterates buy with PT of $16, http://y.ahoo.it/gRezzdY7

  4. $GALT monthly chart http://y.ahoo.it/nZSK4x9D

  5. @moneyjunkie $ANGI $GALT $TWER all gapped then fell back - I prefer weak opens then r/g moves. $DVR better looking setup imo

  6. $GALT today is about consolidation and accumulation. Expect a red close around 6.00 today. Should pick back up tomorrow or wednesday

  7. $GALT where do you see the bottom?

  8. $GALT interesting....

  9. Set-ups for Monday http://y.ahoo.it/j6Yj4AhI other stocks to watch $RSH $AVNR $AAPL $PEIX $INFN $CTXS $ANR $FB $GALT $NPSP $TKMR $DDR $ALKS

  10. @bangersnpip $GALT in play

  11. @micheleciani $GALT patent approval

  12. $GALT 8.37 By Friday!

  13. $GALT http://y.ahoo.it/Vk0E3DJF

  14. $GALT YAAAh!!

  15. $GALT Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy.. http://y.ahoo.it/IExg5JBG

  16. $GALT secures patent for diabetic nephropathy drug http://y.ahoo.it/KC7Ffa4q

  17. $GALT Galectin Therapeutics Inc files Form 8-K (Events or Changes Between Quarterly Reports) SEC Filin.. http://y.ahoo.it/QvjJEG4J

  18. $GALT $7 PT... Last chart of the night... GLTA

  19. 9-15-14 watchlist $ANR $CNDO $GALT $GRH $IVAN $PULS $SOL $USU

  20. Stock Watchlist 15 September: $ANGI $DVR $GALT $TWER #stocks #charts #trading http://y.ahoo.it/KhQ3ncnt

  21. $GALT You wanna be there when they announce any partnership. Could be a week, could be a year...

  22. $GALT Nice day to cap off nice week. Be interesting to see what happens Monday. There is potential for a strong open. Unrealized gain of 22%

  23. $GALT@TradeIdeasQuant are you kidding me? .04 cents down with 4k shares crushed ?? BashideadQuant Lol

  24. $GALT - http://y.ahoo.it/u7Nhcycg - Is Getting Crushed in the Post Market - New postmarket low. Approaching today s low.

  25. $IBB $GALT Galectin Therapeutics $GALT in discussions with large pharmaceutical companies according to a recent presentation